Reported Friday, Biocytogen Announces First Patient Dosed In IDEAYA's Phase 1 Trial Of First-In-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034, Triggering $5M Milestone Payment
Benzinga Newsdesk 8 months ago
News
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA's PARG inhibitor IDE161.IDEAYA
- IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA's PARG inhibitor IDE161.
- IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK.
- First dosing triggers a $5 million milestone payment to Biocytogen under the companies' option and license agreement.